CARLSBAD, Calif. & MOLNDAL, Sweden -- Safety Syringes Inc. and AstraZeneca this week announced the first launch in Germany of oral and injectable Exanta(TM) in its first indication prevention of venous thromboembolic events (VTE) in elective hip or knee replacement surgery (orthopaedic surgery). The European treatment regimen for Exanta involves an early postoperative start of treatment, with initial injectable dosing administered 4-8 hours after the completion of surgery, followed by oral Exanta 24mg twice daily for up to 11 days. This approach supports the increasing use of relatively early postoperative initiation of VTE preventative treatment in clinical practice across Europe.
The injectable form of Exanta (Melagatran AstraZeneca(TM)) is using the UltraSafe(R) Passive(TM) Delivery System to enhance protection of health care personnel against blood transmitted diseases. "Exanta is a new anticoagulant and the first oral treatment in a new class of direct thrombin inhibitors (DTIs), and we are pleased to launch the injectable form of Exanta in an innovative drug delivery system," commented Thomas Rask, Global Brand Manager. "We found the UltraSafe Passive Delivery System to be clearly preferred to standard prefilled syringes because of its safety profile in protecting from needle injuries."
"AstraZeneca is to be commended for their commitment to clinician safety, they have a terrific new treatment regimen and they have been a terrific partner," stated Christer Andreasson, Safety Syringes Inc.'s CEO. "The UltraSafe Passive Delivery System meets or exceeds all needle safety standards to date. It has also proven to be widely preferred by clinicians as a delivery system for injectable medications."
Designed to ensure the ultimate in user preference, compliance and protection, the UltraSafe Passive Delivery System is intended for unit dose, prefilled glass syringe presentations. The easy-to-use, intuitive and innovative system provides an optimal drug delivery system with the preferred passive activation method.
--Founded in 1991, Safety Syringes Inc. is a global market leader for drug delivery systems for pre-filled glass syringes. The UltraSafe Delivery System has been marketed since 1999. U.S. and international patents protect all products developed and marketed by Safety Syringes Inc.
--AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of over $18.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.
-- Exanta(TM) is a trademark of the AstraZeneca group of companies
--UltraSafe(R) Passive(TM) is a registered trademark of Safety Syringes Inc.
COPYRIGHT 2004 Business Wire
COPYRIGHT 2004 Gale Group